Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly...
Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients
About this item
Full title
Author / Creator
Li, Heng , Wang, Zhize , Xiao, Wei , Yan, Libin , Guan, Wei , Hu, Zhiquan , Wu, Lily , Huang, Qihong , Wang, Ji , Xu, Hua , Zhang, Xu and Ye, Zhangqun
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Androgen-deprivation therapy has been the standard treatment for metastatic and locally advanced prostate cancer, but the majority of patients will progress to castration-resistant prostate cancer within 2–3 years. Unlike the case in breast cancer, no clinically validated biomarker has been used to predict the outcomes of androgen-deprivation thera...
Alternative Titles
Full title
Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1957463205
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1957463205
Other Identifiers
ISSN
0893-3952
E-ISSN
1530-0285
DOI
10.1038/modpathol.2017.74
